Clinical trial fails for Progenics Pharmaceuticals
Biopharmaceutical company Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported this morning that its phase 3 clinical trials with Wyeth Pharmaceuticals (NYSE: WYE), for intravenous methylnaltrexone used in patients recovering from segmental colectomy surgical procedures failed. Shares plummeted 55.7%, or $7.55, to $6.00 in pre-market trading.
For detailed price information and recent news stories about Progenics Pharmaceuticals, click PGNX.
About the Author
Reporter Jennifer Schonberger is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: